KCT0003936招募中未知
Multicenter, Randomized, Double-blinded, Active-controlled, Parallel, Phase ? Study to Evaluate the Efficacy and Safety of HL151 versus Talion Tab. in Pruritus cutaneus.
Hanlim Pharmaceutical0 个研究点目标入组 196 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 196
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 19(Year) 至 o Limit（—）
- 性别
- All
入选标准
- •1) Both gender, 19 years = age
- •2) Patients with pruritus due to the following diseases
- •? acute eczema, chronic eczema, monetary eczema, sebaceous deficiency eczema
- •? contact dermatitis, atopic dermatitis, seborrheic dermatitis, neurodermatitis
- •? Acute prurigo (Strofus, Urticaria, lichen urticatus), subacute prurigo, chronic prurigo (nodular prurigo)
- •? systemic skin pruritus, focal skin pruritus
- •3) In visit 2, during the run-in period previous week the VAS score of day and night time were 2 or more average points per day (maximum 4 points)
- •4) Those who can ability to record subject diary
- •5) Written consent voluntarily to participate in this clinical trial after understanding and detailed explanation about this clinical trial
排除标准
- •1) Patients with pruritus due other medical causes (liver disease, heart failure, etc.)
- •2) Among patients with skin disease, malignant tumors and patients with chronic urticaria skin disease
- •3) Patients with systemic infection symptoms at the time of clinical trials
- •4) Asthmatic patients requiring steroid treatment
- •5) Patients with Spastic diseases such as epilepsy
研究者
相似试验
招募中
不适用
Multi-center, Randomized, Double-blinded, Active-controlled, 12-weeks, Non-inferiority phase 3 trial to Evaluate the Efficacy and Safety of IMD-Omega Soft Cap. in the complex (IIb) patients with hypertriglyceridemia and hypercholesterolemiaEndocrine, nutritional and metabolic diseasesKCT0009700IMDPharm240
进行中（未招募）
不适用
Multicentre, randomized, double-blind, active comparator-and placebo-controlled, parallel-group phase III clinical study for the evaluation of Diclofenac HPBCD 25, 50 mg/ml administered as a single s.c. dose, in the treatment of acute moderate-to-severe post-surgical pain from dental surgery (impacted 3rd molar extraction)acute moderate-to-severe post-surgical pain from dental surgery (impacted 3rd molar extraction)MedDRA version: 9.1Level: HLTClassification code 10044049Term: Dental pain and sensation disordersEUCTR2009-011663-37-GBIBSA, Institut Biochimique SA300
进行中（未招募）
不适用
Multicenter, Randomized, Double-Blind, Active-Controlled Trial Comparing REMICADE® (infliximab) and REMICADE® plus Azathioprine to Azathioprine in the Treatment of Patients with Crohn’s Disease Naive to both Immunomodulators and Biologic Therapy (Study of Biologic and Immunomodulator Naive Patients in Crohn’s Disease) SONIC - SONICmoderate to severe Crohn’s DiseaseMedDRA version: 8.1Level: LLTClassification code 10011401Term: Crohn's diseaseEUCTR2004-002815-10-DECentocor B.V.500
进行中（未招募）
不适用
Multicenter, Randomized, Double-Blind, Active-Controlled Trial Comparing REMICADE® (infliximab) and REMICADE® plus Azathioprine to Azathioprine in the Treatment of Patients with Crohn’s Disease Naive to both Immunomodulators and Biologic Therapy (Study of Biologic and Immunomodulator Naive Patients in Crohn’s Disease) SONIC - SONICmoderate to severe Crohn’s DiseaseMedDRA version: 8.1Level: LLTClassification code 10011401Term: Crohn's diseaseEUCTR2004-002815-10-DKCentocor B.V.500
进行中（未招募）
不适用
Multicenter, Randomized, Double-Blind, Active-Controlled Trial Comparing REMICADE® (infliximab) and REMICADE® plus Azathioprine to Azathioprine in the Treatment of Patients with Crohn’s Disease Naive to both Immunomodulators and Biologic Therapy (Study of Biologic and Immunomodulator Naive Patients in Crohn’s Disease) SONIC - SONICmoderate to severe Crohn’s DiseaseMedDRA version: 7.1Classification code 10011401EUCTR2004-002815-10-ATCentocor B.V.500